All Releases
 |
Mylan's President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
Nov 18, 2009
|
7.1 KB |
|
| |
PITTSBURGH, Nov 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that Didier Barret, president of Mylan Europe, Middle East and Africa (EMEA), has been elected president of the European Generic Medicines Association (EGA). Barret was elected to a two-year term earlier today at the EGA annual meetin...
|
|
Mylan's Spanish Business Named Best Generic Pharmaceuticals Company in Spain by Elsevier
Nov 12, 2009
|
6.6 KB |
|
| |
PITTSBURGH, Nov 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan SA has received the prestigious 2009 Elsevier Galien Award for Best Generics Company in Spain. The award recognizes the company's outstanding development in the country during the last year and its introducti...
|
|
Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix Laboratories
Nov 10, 2009
|
6.8 KB |
|
| |
PITTSBURGH, Nov 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR)...
|
|
Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32
Oct 29, 2009
|
32.6 KB |
|
| |
PITTSBURGH, Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and nine months ended September 30, 2009.
Financial Highlights
-- Adjusted diluted EPS of $0.32 and $0.97 for the three and nine months
ended September 30, 2009, compared to $0.23 an...
|
|
Dey Launches and Unveils Next-Generation, Needle-Protected EpiPen(R) (Epinephrine) Auto-Injector with Enhanced Patient-Friendly Features
Oct 26, 2009
|
12.3 KB |
|
| |
BASKING RIDGE, N.J., Oct 26, 2009 /PRNewswire via COMTEX News Network/ -- Dey Pharma, L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today launched a newly designed, patient-friendly EpiPen(R) Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with se...
|
|
For Parents of Kids with Food Allergies, the Scariest Thing at Halloween is the Trick-or-Treat Bag
Oct 23, 2009
|
18.4 KB |
|
| |
BASKING RIDGE, N.J., Oct 23, 2009 /PRNewswire via COMTEX News Network/ -- The haunted happenings of Halloween are upon us and soon we'll be carving pumpkins, dressing in costumes and telling spooky stories. But if your child has a food allergy, what's at the bottom of his or her trick-or-treat bag may be more frightening than any ghost or goblin.
...
|
|
Mylan Declares Quarterly Preferred Stock Dividend
Oct 20, 2009
|
6.3 KB |
|
| |
PITTSBURGH, Oct 20, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that in accordance with its 2.139 million preferred stock issuance, the company has declared its quarterly dividend of $16.25 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share) pa...
|
|
Mylan Resolves Longstanding Dispute with DOJ Regarding Certain Medicaid Rebate Classifications from 2000 Through 2004
Oct 19, 2009
|
7.7 KB |
|
| |
PITTSBURGH, Oct 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that two of its subsidiaries have resolved a longstanding dispute with the U.S. Department of Justice relating to certain Medicaid rebate classifications. Mylan's subsidiaries Mylan Pharmaceuticals Inc. and UDL Laboratories Inc. settl...
|
|
Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
Oct 15, 2009
|
6.7 KB |
|
| |
PITTSBURGH, Oct 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Topiramate Capsules (Sprinkle), 15 mg and 25 mg.
Topiramate Cap...
|
|
Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
Oct 14, 2009
|
6.2 KB |
|
| |
PITTSBURGH, Oct 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast on Thursday, Oct. 29, 2009, at 10:00 a.m. ET, to review the company's financial results for the third quarter 2009, which ended Sept. 30. Mylan will release its financial results on...
|
|
Mylan Announces Settlement Agreement Related to Vfend(R) First-to-File Opportunity
Oct 14, 2009
|
7.5 KB |
|
| |
PITTSBURGH, Oct 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that the company's Mylan Pharmaceuticals and Matrix Laboratories subsidiaries entered into a settlement and license agreement with Pfizer Inc. relating to Voriconazole Tablets, 50 mg and 200 mg, the generic version of Pfizer's Vfend(R...
|
|
Mylan Receives FDA Approval for Generic Version of Parkinson's Treatment Sinemet(R)
Sep 30, 2009
|
6.7 KB |
|
| |
PITTSBURGH, Sept 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and ...
|
|
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
Sep 16, 2009
|
7.4 KB |
|
| |
PITTSBURGH, Sept 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug A...
|
|
FDA Accepts for Filing Mylan's ANDA for Generic Copaxone(R)
Sep 14, 2009
|
6.1 KB |
|
| |
PITTSBURGH, Sept 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Mylan Pharmaceutical Inc.'s abbreviated new drug application (ANDA) for Glatiramer Acetate Injection (20 mg/mL), a generic version of Teva's Copaxone(R), a prod...
|
|
Dey Issues Advisory
Sep 11, 2009
|
6.7 KB |
|
| |
NAPA, Calif., Sept 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today issued an advisory regarding the theft of two different types of its respiratory medications, Ipratropium Bromide Inhalation Solution, 0.02%, and Albuterol Sulfate Inhalation Solution, 0.083%, unit-dose vials. The ...
|
|
Mylan Parts Ways with Chief Financial Officer Jolene Varney
Sep 8, 2009
|
6.1 KB |
|
| |
PITTSBURGH, Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced its decision to part ways with its chief financial officer. Executive recruiting firm Korn/Ferry International will resume its search immediately for a qualified candidate and, in the interim, Mylan will continue business as usual.
...
|
|
Mylan Launches First Generic Version of Xopenex(R) Inhalation Solution (Concentrate), 0.25%
Sep 1, 2009
|
6.5 KB |
|
| |
PITTSBURGH, Sept 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched levalbuterol inhalation solution USP (Concentrate), 0.25%, (1.25 mg/0.5 mL). Mylan, which has already launched the product, will market this product with 180 days of exclus...
|
|
Mark W. Parrish Joins Mylan's Board of Directors
Sep 1, 2009
|
7.4 KB |
|
| |
PITTSBURGH, Sept 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that Mark W. Parrish, chairman and CEO of Trident USA Health Services, the nation's largest provider of mobile X-ray and laboratory services to the long-term care industry, has joined Mylan's Board of Directors. In addition to his cu...
|
|
Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
Aug 27, 2009
|
7.0 KB |
|
| |
PITTSBURGH, Aug. 27 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market 1% Clindamycin and 5% Benzoyl Peroxide Gel based on a...
|
|
Mylan Files Lawsuit Against Pittsburgh Post-Gazette
Aug 19, 2009
|
7.8 KB |
|
| |
PITTSBURGH, Aug. 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL)
today announced that the company and its subsidiary Mylan Pharmaceuticals Inc.
filed a civil lawsuit in the Circuit Court of Monongalia County, W.Va.,
against the Pittsburgh Post-G...
|
|
|